CorMedix Inc.CRMD

CorMedix Inc. spent the first half of 2026 swapping auditors, filing an S-8 to create more shares, and quietly increasing inventory by $1 million while reporting $127.4 million in revenue for the quarter ending March 31. The company’s 10-Q shows $38.6 million net income and $178.1 million in cash, but the real headline is the board’s decision to dismiss CBIZ CPAs on July 1 and appoint a new firm the same day, a move that arrived just after the old firm had signed off on the very same quarterly report. The numbers are filed; the story is in the footnotes. (source: CRMD 8-K 2026-07-01, https://www.sec.gov/Archives/edgar/data/1410098/000141009826000037/crmd-20260625.htm)

CorMedix sells Vabomere, an intravenous antibiotic used in hospitals, and its product page promises prevention of cardiac, renal and infectious diseases. The company’s website carries the same promise in six identical banners, a design choice that suggests either strong conviction or a content team that ran out of adjectives. The balance sheet, by contrast, carries the conviction of hard cash: $437 million in shareholders’ equity, $42.4 million in operating cash flow, and a $30.7 million inventory balance that rose by $1 million in the quarter. Whether hospitals are ordering ahead or the sales team is over-forecasting remains a matter of interpretation, but the cash register is at least ringing. (source: CRMD 10-Q 2026-03-31, https://www.sec.gov/Archives/edgar/data/1410098/000141009826000040/crmd-20260629.htm)

CorMedix’s diluted EPS came in at $0.43 on 93 million shares for the quarter, a figure that would feel more robust if the share count hadn’t been boosted by a June 25 S-8 that created new shares for unspecified purposes. The company’s 2025 revenue was $311.7 million, but the first quarter of 2026 recognised only $127.4 million, a gap the filings label as normal seasonality. Meanwhile, R&D spend was $7.2 million, a figure that looks modest until you compare it with the $729,000 spent on property, plant and equipment-an investment profile that says ‘antibiotics first, offices second.’ The cash position remains healthy at $178.1 million, but the company’s market profile looks less like a scaled commercial player and more like a small-cap that still has to prove it can grow beyond a single marketed product. (source: CRMD 10-Q 2026-03-31, https://www.sec.gov/Archives/edgar/data/1410098/000141009826000040/crmd-20260629.htm)

CorMedix trades on the Nasdaq under the ticker CRMD, a venue that has seen the stock range between roughly $3 and $5 over the past year, a span that reflects neither euphoria nor despair but rather the classic micro-cap rhythm of ‘wait for the next catalyst.’ The company’s investor-relations page lists a corporate update on May 14, 2026 and a first-quarter results release the same day, both events that arrived without a whisper of guidance or a concrete read-through on Vabomere uptake. For now, the chart is a flat line with mild undulations, and the only real movement is in the footnotes. (source: CRMD SEC submissions JSON, https://data.sec.gov/submissions/CIK0001410098.json)

The evidence base is thin on commercial momentum beyond the filed numbers. The company’s product rail shows Vabomere and a promise of prevention, but the filings do not quantify hospital orders, formulary wins, or revenue per hospital. The Schedule 13G/A updates on June 12 show a 5.7% beneficial owner trimming its stake, a signal that some investors read as ‘wait and see’ rather than ‘full speed ahead.’ The next quarterly 10-Q will show whether revenue growth has caught up with inventory build, and whether the new auditor brings either credibility or another bill to footnote. Until then, CorMedix’s story is the gap between the product brochure and the cash register receipts. (source: CRMD Schedule 13G/A 2026-06-12, https://www.sec.gov/Archives/edgar/data/1410098/000206383726000003/xslSCHEDULE_13G_X02/primary_doc.xml)